Nutra Pharma Taps Venom Expert as President and Chief Executive Officer.

Business Editors

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Nov. 7, 2002

Deitsch's Work With Gila Monsters, Cone Snails and Venomous Snakes to

Add Critical Component To Nutra Pharma's Immunokine Drug Platform

Developed From Thailand Cobra Venom

Nutra Pharma Corp. (OTCBB: NPHC) announced today that it has named Rik Deitsch as its President and Chief Executive Officer. Mr. Deitsch replaces Dr. Harold Crews and Dr. Edith Martin, who resigned from their positions as Chief Executive Officer, President and members of the Board of Directors respectively. Mr. Deitsch has been named to the Board of Directors.

Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted research for the Duke University Medical School Comprehensive Cancer Center. His research provided some of the beginning fundamentals for the development of several powerful therapeutics. Mr. Deitsch has a strong background in researching compounds derived from venomous animals, conducting work in Gila monsters (i.e. Exendin 4 -- Amylin Pharmaceuticals), Cone Snails (i.e. Prialt -- Elan Pharmaceuticals), and Rattlesnakes (i.e. Integrilin -- Millennium Pharmaceuticals). His graduate work consisted of in-depth research on Cone snail venom pharmaceutical applications and Camptothecin analogs for the treatment of cancer. Deitsch has several papers and posters on rational drug design using computer simulations. Mr. Deitsch is an adjunct professor and teaches several courses for Florida Atlantic University's College of Business and Continuing Education Department.

Venom-based therapeutic drugs have received attention lately for their effectiveness in addressing a variety of diseases. The New York Times reported that Eli Lilly will pay Amylin Pharmaceuticals approximately $325 million for the rights to 50% of domestic profits and 80% of international profits for a diabetes drug being developed from Gila monster venom.

"Bio-prospecting compounds from venomous animals has proven to be highly successful. Venoms are a rich source of biologic activity for drug development," said Rik Deitsch, Nutra Pharma's President and CEO. "Of all the venom studies being conducted, Alpha-Cobratoxin has yielded the greatest number of indications due to the fact that it is immunomodulatory, meaning that it has the ability to modulate human immune response. This has far-reaching therapeutic applications in everything from viral infections to autoimmune etiologies," he added.

The Company's research has yielded a breakthrough class of therapeutic peptides collectively referred to as "Immunokines." This peptide technology has created new opportunities for the relief and treatment of a variety of devastating neurological and viral disorders, most of which are currently without satisfactory therapies Immunokine has been shown to be beneficial in the treatment of Cancers, HIV infections, Herpes, as well as viral diseases specific to animals. Immunokine also has the potential to treat Hepatitis C infections in humans.

Mr. Deitsch also intends to combine his expertise in rational drug design and bioinformatics with Nutra Pharma's proprietary and patented method for altering the three dimensional structure of certain proteins and peptides that results in the preservation of receptor-binding characteristics. The binding of specialized signaling proteins and peptides to cell surface receptors is an important part in the pathogenesis and progression of many different diseases. By modifying peptides which do not activate the normal biochemical pathways necessary for disease progression, powerful therapeutic agents could restore normal function to diseased tissue or exert a beneficial immunomodulatory effect.

About Nutra Pharma Corp.

Nutra Pharma is a biopharma company focused on the optimization of protein compounds in order to achieve maximum therapeutic practicability (enhanced efficacy, minimized toxicity and ease of administration). The Company is engaged in the discovery and development of novel peptide therapeutics and drug delivery systems for the treatment of several different human and companion animal diseases. The Company's core technology revolves around the derivation of specialized receptor-binding peptides from natural proteins and peptides found in nature. Product candidates include Multiple Sclerosis, HIV, Herpes, Hepatitis C and Cancer.

This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Nutra Pharma Corp., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For information and investor relations, please contact: Investor Relations at 800/715-9999 or e-mail [e-mail].